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Abstract: The vertiginous increase in the use of extracellular vesicles and especially exosomes
for therapeutic applications highlights the necessity of advanced techniques for gaining a deeper
knowledge of their pharmacological properties. Herein, we report a novel chemical approach for
the robust attachment of commercial fluorescent dyes to the exosome surface with covalent binding.
The applicability of the methodology was tested on milk and cancer cell-derived exosomes (from
U87 and B16F10 cancer cells). We demonstrated that fluorescent labeling did not modify the original
physicochemical properties of exosomes. We tested this nanoprobe in cell cultures and healthy mice
to validate its use for in vitro and in vivo applications. We confirmed that these fluorescently labeled
exosomes could be successfully visualized with optical imaging.
Keywords: extracellular vesicles; exosomes; vesicle labeling; optical imaging; fluorescence
1. Introduction
Exosomes are considered the smallest extracellular vesicles (50–150 nm) of endosomal
origin [1]; their structures consist of a lipid bilayer membrane derived from the parent cell
membrane [2]. Based on their physicochemical and structural properties, exosomes con-
stitute a natural alternative to synthetic nanoparticles for developing novel drug delivery
systems (DDS). In particular, they are especially suited to substituting for liposomes, due to
their similar size and morphology [3,4]. In addition, the roles of exosomes in neural commu-
nication and pathological states, such as inflammation, tumorigenesis, and pre-metastatic
niche formation [5,6], suggest that they could serve as a natural bio-targeting agent, with
better accumulation properties, compared to synthetic nanoparticles [7]. Among the differ-
ent types of exosomes extracted from natural sources, those derived from plants or food
(including milk exosomes) have been widely tested as natural nanoplatforms in therapy
and diagnostics due to their low toxicity and lack of immunogenicity [8,9]. Milk exosomes
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are particularly interesting because their production is suitable, scalable, and economic,
and their strength and stability are superior to those of other exosomes [10–12]. These
properties support the further development of exosomes as a DDS for translation into the
clinical field.
Although exosomes have shown promise as a DDS in preclinical research [11,13], the
transfer of these nanovesicles into the clinical field for therapeutic applications requires
a better understanding of their in vivo behavior, particularly their biodistribution and
organ/tissue targeting capabilities. Non-invasive imaging techniques can provide accurate
in vivo information about their pharmacokinetics and biodistribution. Among the different
techniques applied in biomedical research, fluorescence confocal imaging is currently
highly popular because it provides detailed microscopic images easily, cost-effectively, and
rapidly. Optical imaging also offers a highly versatile platform for non-invasive in vivo
imaging due to its high sensitivity and the possibility of using a wide variety of probes,
based on proteins, enzymes, or antibodies. In addition, optical imaging does not require
ionizing radiation, unlike other techniques, such as nuclear (i.e., single photon emission
computed tomography or positron emission tomography) or X-ray imaging.
During the last few years, different approaches have been developed for the applica-
tion of optical imaging to in vitro and in vivo evaluations of extracellular vesicles. These
approaches vary from genetic engineering methods for incorporating bioluminescent pro-
teins [14] or green fluorescent protein (GFP) [15] into the exosome structure, to directly
labeling exosomes with fluorescent lipophilic dyes [16]. Due to the complexity of the
genetic engineering approach, the use of fluorescent dyes has become the gold standard
for visualizing exosomes. Currently, the integration of lipophilic fluorophores, such as
dialkylcarbocyanine or PKH dyes, into the exosomal membrane represents the most widely
used labeling methodology, due to its simplicity and low cost [17]. Nevertheless, some
drawbacks limit the use of labeled exosomes, such as excessive exosome aggregation, the
weak bond between the exosome and the fluorophore, which can cause the release of the
dye from the exosome to non-targeted cells/tissues, and the instability of the resulting
probes, which can result in false signals in optical imaging [17–19].
Here, we describe a direct, straightforward, covalent method for labeling exosomes
with commercial fluorescent dyes, which enables in vitro and in vivo assessments with
optical imaging techniques.
2. Experimental Section
2.1. Isolation of Milk Exosomes
Exosomes were isolated from commercial, fresh pasteurized, semi-skimmed goat
milk (El Cantero de Letur, Albacete, Spain). Samples were centrifuged at 4 ◦C in 30-mL
polycarbonate tubes, in an AVANTI J-30I centrifuge equipped with a Ja 30,50 Ti fixed-angle
rotor (Beckman Coulter Instruments, Brea, CA, USA). Briefly, milk was centrifuged 10 min
at 5000 G and treated with microbial rennet to remove fat globules and milk casein. The
resultant supernatant was successively centrifuged for 10 min at 5000 G, 35 min at 13,000 G,
and 15 min at 35,000 G to exclude contaminants, such as cell debris and large vesicles. Then,
the milk whey was ultracentrifuged at 100,000 G for 70 min to precipitate the exosomes.
The resultant pellet was washed three times with phosphate-buffered saline (1× PBS)
and additionally purified in PD-10 size-exclusion columns (GE Healthcare Bio-Sciences,
Uppsala, Sweden). The exosomes were concentrated to achieve the required volume by
ultracentrifugation at 100,000 G for 90 min. The nanovesicles pellet was dispersed in 100 µL
1× PBS and stored at −20 ◦C until characterization and subsequent labeling. G values
described on the isolation protocol refer to the average relative centrifugal force reached
during the centrifugation step, after 5 min acceleration.
2.2. Cancer Cell Culture
Glioblastoma (U87) and mouse melanoma (B16F10) cell lines were kindly provided by
the Cell Culture Unit of the Experimental Medicine and Surgery Unit at Hospital General
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Universitario Gregorio Marañón (Madrid, Spain) and Centro Nacional de Investigaciones
Oncológicas (CNIO) Carlos III (Madrid, Spain), respectively. These cell lines were cultured
in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, ThermoFisher Scientific, Waltham,
MA, USA) supplemented with 10% fetal bovine serum (FBS; exosome-free, Gibco, Ther-
moFisher Scientific, Waltham, MA, USA) and 1% L-glutamine, at 37 ◦C, 5% CO2, and
controlled humidity in 95% air.
In order to remove extracellular vesicles present in serum, FBS was ultracentrifuged
at 100,000 G and 4 ◦C for 18 h.
2.3. Isolation of Cancer Cell Line-Derived Exosomes
Exosomes were isolated from cancer cell lines U87 and B16F10 according to previous
protocols [20]. Briefly, once cells reached approximately 80 % confluence, the cell culture
was placed in polycarbonate tubes, and exosomes were harvested in four successive
centrifugations at 4 ◦C, with an AVANTI J-30I centrifuge equipped with a Ja 30,50 Ti fixed-
angle rotor (Beckman Coulter Instruments, Brea, CA, USA). The centrifugation steps were:
first 10 min at 300 G, then 10 min at 2000 G, then 30 min at 10,000 G, and finally 70 min
at 100,000 G. The nanovesicles pellet obtained was washed with 1× PBS and re-isolated
at 100,000 G for 70 min. The final pellet of exosomes was dispersed in 200 µL of 1× PBS
and stored at −20 ◦C until characterization and subsequent labeling. G values described
on the isolation protocol refer to the average relative centrifugal force reached during the
centrifugation step, after 5 min acceleration.
2.4. Protein Content Determination
The protein contents of unlabeled exosomes suspensions were quantified with the
Bradford–Coomassie colorimetric assay. This assay employed a ready-to-use Coomassie
staining reagent (Sigma-Aldrich, St. Louis, MO, USA), and the assay was performed
according to the manufacturer’s instructions. Absorbance was measured with a Synergy™
HT Multi-Mode Microplate Reader (Biotek Instruments Inc., Winooski, VT, USA).
2.5. Fluorescent Labeling of Exosomes
Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA) and used without further purification. Commercial SCy 7.5 and BDP-FL succin-
imidyl ester fluorophores were acquired from Lumiprobe (Hannover, Germany).
Synthesis of SCy-Exo: a solution of 75 µg exosomes (from goat milk, B16F10, or U87)
in 100 µL 1× PBS was mixed with 10 µL SCy 7.5 (17 mM) at pH = 8.5 (with NaHCO3
0.1 M) and vortexed for 2 h at 4 ◦C. The product was purified with Exosome Spin Columns
(Invitrogen, Carlsbad, CA, USA).
Synthesis of BDP-Exo: a solution of 75 µg exosomes (from goat milk) in 100 µL 1× PBS
was mixed with 10 µL BDP-FL (25 mM) at pH= 8.5 (with NaHCO3 0.1 M), and vortexed for
2 h at 4 ◦C. The product was purified with Exosome Spin Columns (Invitrogen, Carlsbad,
CA, USA).
2.6. Physicochemical Characterization
The morphology and size of exosomes were evaluated at ICTS Centro Nacional de
Microscopía Electrónica (Universidad Complutense de Madrid, Spain). They employed
TEM (JEOL JEM-1010, JEOL USA Inc., Peabody, MA, USA), which operated at 100 kV.
Exosomes were negatively stained with uranyl acetate on formvar carbon-coated copper
grids at room temperature. The hydrodynamic sizes of control and labeled exosomes
samples were measured with a Zetasizer Nano system (Malvern Panalytical, Malvern, UK).
Concentrations (particles/mL) of exosomes in suspension as well as nanoparticles size
were measured with a NanoSight NS500 (Malvern Panalytical, Malvern, UK), from Centro
Nacional de Investigaciones Oncológicas (CNIO, Madrid, Spain), equipped with a high
sensitivity sCMOS camera. Camera level and threshold were established in 11 and 10,
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respectively. Videos were recorded in static conditions and analyzed with NTA 3.1 Build
software, and three replicate histograms were obtained for each sample
2.7. Flow Cytometry Analysis
Unlabeled and fluorescently labeled exosomes were evaluated with a GalliosTM
10 color Flow Cytometer (Beckman Coulter Instruments, Brea, CA, USA). A blue-light laser
(488 nm; BODIPY 550 SP filter) was employed for analyzing exosomes labeled with BDP-FL.
A red-light laser (635 nm; 725/20 filter) was employed for analyzing exosomes labeled
with SCy 7.5. The maximum number of events was not restricted during the measurement.
For discriminating exosomes from other non-specific events and background, a delimited
region was placed in the flow cytometry dot-plot; this gate was adjusted to the expected
size range of exosomes.
Flow cytometry data were analyzed with KaluzaTM Acquisition Software (version
1.5; Beckman Coulter, Brea, CA, USA).
2.8. In Vitro Stability of Fluorescent Exosomes
In vitro stability was assessed by incubating 75 µg milk exosomes labeled with BDP-
FL (BDP-MiExo) in 1× PBS for 72 h at 37 ◦C. At baseline (0 min), 12 h, 48 h, and 72 h, the
samples were collected and measured with a HPLC system (Agilent 1200 series; Agilent
Technologies, Santa Clara, CA, USA), equipped with a UV absorbance detector and a Yarra
SEC-3000 column (300 × 7.8 mm; Phenomenex Inc., Torrance, CA, USA). An isocratic gra-
dient of 1× PBS with a flow rate of 0.2 mL/min was employed with a UV measurement at
503 nm. In addition, HPLC chromatogram of non-labeled milk exosomes was performed to
confirm purity of the sample using same gradient and column but with a UV measurement
at 254 nm.
2.9. Isolation of Primary Mouse Hepatocytes
Animal experiments conducted this project complied with the ARRIVE guidelines
and were in accordance with the EU Directive (2010/63/EU) for animal experiments. The
HGUGM Animal Care and Use Committee approved all procedures.
Hepatocytes were isolated from adult C57BL/6 mice (12–16 weeks old). These mice
were genetically engineered to expressed enhanced green fluorescent protein EGFP on
hepatocyte plasma membranes (mG) and Tomato-dye protein on the plasma membranes
(mT) of other cell-types. Mice were generated with the Cre/LoxP system by crossing female
mice that expressed Cre-recombinase under the control of the albumin promoter (AlbCre
mice, B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J, stock# 3574, Jackson Lab, Farmington, CT,
USA) and male mice that expressed the double-fluorescent Cre reporter (mT/mG mice;
B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, stock# 7676, Jackson Lab,
Farmington, CT, USA) [21].
Primary mouse hepatocytes were isolated with a two-step protocol for hepatic per-
fusion from the inferior cava vein, according to previously published protocols [22], with
some modifications. Briefly, the liver was first perfused with Hank’s Balanced Salt Solution
(without calcium, magnesium, or phenol-red; Gibco, ThermoFisher Scientific, Waltham,
MA, USA), containing 10 mM HEPES (pH 7.4), 0.2 mM EGTA, and 10 U/mL heparin.
This was followed by perfusion with Williams E Medium (Gibco, ThermoFisher Scientific,
Waltham, MA, USA), containing 10 mM HEPES (pH 7.4) and 0.4 mg/mL collagenase
type IV from Clostridium histolyticum (Sigma-Aldrich, St. Louis, MO, USA). After fil-
tering the digested liver through a 100 µm-pore cell strainer, cells were resuspended in
attachment media (DMEM:F12 with 10% FBS supplemented with 5 mM sodium pyruvate,
2 mM L-glutamine, 0.05% NaHCO3, 20 mM HEPES, 0.12% glucose, 0.02% BSA, 100 U/mL
penicillin, and 100 µg/mL streptomycin). Next, the mixture was centrifuged at 50 G,
and purified with density gradient centrifugation in an isotonic solution of Percoll (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden). After a wash in attachment media with a
50 G centrifugation, cell viability was checked with Trypan blue.
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2.10. Confocal Studies of in Vitro Uptake
A 24-well cell culture plate (Corning, NY, USA) was pretreated with a 1:1000 solution
of collagen type (I), and one round glass coverslip was added per well. Isolated primary
mouse hepatocytes were seeded at a density of 20,000 cells per well and cultured overnight
in attachment medium under controlled humidity conditions, in 95% air and 5% CO2, at
37 ◦C. Next, cells were incubated for 30 min, 60 min, 120 min, 240 min, and 24 h with
5 µg/mL (2.5 µg/well) or 0.5 µg/mL (0.25 µg/well) milk exosomes labeled with SCy
7.5 (SCy-MiExo). Next, the hepatocytes were washed twice with PBS and fixed with
4% paraformaldehyde (PFA) for 5 min. After removing the PFA and washing with PBS,
the glass coverslips were placed on confocal slides and mounted with DAKO mounting
medium (Agilent Technologies, Santa Clara, CA, USA), which contained DAPI fluorescent
dye, for nuclei staining.
NIR fluorescent signals from SCy-MiExo were captured with a Leica-SPE microscope
(Leica Microsystems Inc., Buffalo Grove, IL, USA) equipped with a 635 nm laser. Images
were processed with Fiji ImageJ Software (U. S. National Institutes of Health, Bethesda,
MD, USA). Exosome uptake was assessed by measuring the fluorescent signals in regions
of interest (ROIs) in the perinuclear region of the cell.
2.11. In Vivo Optical Imaging
Fluorescent milk exosomes (SCy-MiExo) were administered to healthy CD1 female
mice (n = 3 animals, weight 20–25 g). Mice were previously shaved in the abdominal
region, and SCy-MiExo solutions were intravenously injected through the lateral tail vein
(25 µg, 150 µL in 1X PBS). The in vivo biodistribution of SCy-MiExo was evaluated with an
in vivo imaging system (IVIS Spectrum System; PerkinElmer Inc., Waltham, MA, USA) at
1 h, 4 h, and 24 h after injection. During image acquisition, mice were maintained under
1.5–2% isofluorane. Fluorescent detection was performed with an indocyanine green filter
set (excitation: 710/760 nm, emission: 810/875 nm), and the exposure time was under 0.5 s.
To evaluate the natural behavior of the free SCy 7.5 dye, we conducted a control study with
healthy CD1 female mice (n = 2, weight 20–25 g). Briefly, mice received an intravenous
injection of commercial SCy 7.5 (17 mM, 150 µL, in 1× PBS). The imaging conditions were
the same as those described above for SCy-MiExo imaging, except the exposure time was
reduced to 0.2 s. All animals were sacrificed at 24 h post-injection, and the liver, spleen,
kidneys, intestines, heart, lungs, brain, and skin were harvested and imaged with the same
device.
Fluorescence images were quantified with Living Image Software provided with the
IVIS Spectrum System (PerkinElmer Inc., Waltham, MA, USA). We measured the average
radiant efficiency of the SCy-MiExo fluorescent signal from ROIs in all the excised organs.
The average radiant efficiency was defined as the number of photons (p) that left a square
centimeter of tissue per second and radiated into a solid angle of one steradian (sr). The
resulting values, expressed in (p/s/cm2/sr)/(µW/cm2), were normalized to the integration
time, binning, f/stop, field of view, illumination intensity, and the ROI area, to ensure
comparability between measurements.
2.12. Histological Analysis of Hepatic Tissue
At 24 h after the in vivo imaging, mice inoculated with SCy-MiExo, (intravenous
administration, n = 3) were sacrificed, and livers were collected. Tissues were prepared for
both confocal microscopy and histopathological analysis. Briefly, organs were fixed in 4%
PFA for 24 h, transferred to 70% ethanol, and embedded in paraffin for routine hematoxylin
and eosin histochemical staining.
For confocal imaging, liver tissues were fixed in 4% PFA for 24 h, dehydrated in a
sucrose solution, and embedded in optimal cutting temperature compound (OCT) for
cutting into 10-µm sections. Images were acquired with a Leica SP5 microscope (Leica
Microsystems Inc., Buffalo Grove, IL, USA) equipped with a 633-nm excitation laser,
combined with a 10× dry-objective and a 20× oil-immersion objective. Image processing
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was carried out with LAS-AF 2.7.3. build 9723 Software incorporated into the microscope
and with Fiji ImageJ Software (U. S. National Institutes of Health, Bethesda, MD, USA).
2.13. Data Analysis
Data processing and graph construction were performed with Prism 6.0c software
(GraphPad Software, La Jolla, CA, USA). Data are expressed as the mean ± standard
deviation.
Statistical analysis of the in vitro uptake was performed using one-way ANOVA and
Tukey’s multiple comparison test with Prism 8.4.3 software (GraphPad Software, La Jolla,
CA, USA), after checking for normality. Significant differences stand for: * (p ≤ 0.05),
** (p ≤ 0.01), *** (p ≤ 0.001), **** (p ≤ 0.0001).
3. Results
The optimized labeling strategy we developed was successful and robust, based on a
complete physicochemical characterization of fluorescent nanovesicles derived from milk
and cancer cell lines. These novel nanoprobes displayed in vitro and in vivo stability. The
applicability of these probes was evaluated by assessing uptake in primary hepatocytes
and biodistribution in healthy mice, with confocal microscopy and in vivo optical imaging.
3.1. Characterization of Fluorescent Milk Exosomes
Purified milk exosomes (MiExo) labeled with bodipy FL (BDP-FL) and sulfo-cyanine
7.5 (SCy 7.5) showed bright orange and green colors, respectively (Figure 1A). To determine
the successful attachment of the dye to the exosomes, we compared unlabeled exosomes to
purified fluorescent exosomes with flow cytometry. For unlabeled milk exosomes, 0.44% of
events emitted a fluorescent signal at 503 nm and 0.05% of events emitted a fluorescent
signal at 778 nm. For BDP-MiExo and SCy-MiExo, we observed fluorescent signals in
99.56% (at 503 nm) and 99.98% (at 778 nm) of the events, respectively (Figure 1D).
Transmission electron microscopy (TEM) analyses of fluorescently labeled exosomes
showed ‘cup-shaped’ structures typical of extracellular vesicles. The core size was similar
to that of control unlabeled nanovesicles (Figure 1B), with no morphological alterations.
A dynamic light scattering (DLS) analysis showed that the hydrodynamic sizes were
135.31 ± 13.10 nm for BDP-MiExo and 135.33 ± 9.43 nm for SCy-MiExo (Figure 1C). With
both fluorescent labels, the exosomes slightly increased in hydrodynamic size, compared
to the control exosomes (126.12 ± 2.94 nm). Size measurements obtained by Nanoparticle
tracking analysis (NTA) for fluorescent labeled exosomes registered quite similar values
for SCy-MiExo (134.30 ± 8.50 nm) and BDP-MiExo (140.40 ± 6.30 nm). This technique also
reported concentrations of 1.02 × 109 ± 6.20 × 107 particles/mL for BDP-MiExo and 1.65
× 109 ± 1.18 × 108 particles/ml for SCy-MiExo, slightly lower values than those measured
for the unlabeled exosome solution (5.62 × 109 ± 2.29 × 108 particles/mL).
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sulfo-cyanine 7.5 (SCy 7.5, green), and the resulting fluorescently labeled exosomes in dilution fluids. (B) 
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of nanovesicles, evaluated with dynamic light scattering. Data are expressed as the mean ± standard 
deviation; (D) Flow cytometry results show the abundances of control exosomes (grey) and fluorescent 













Figure 1. Optical labeling and physicochemical characterization of control and fluorescence-labeled milk exosomes (MiExo).
(A) Chemical strategies for labeling exosomes with Bodipy FL (BDP-FL, orange) and sulfo-cyanine 7.5 (SCy 7.5, green),
and the resulting fluorescently labeled exosomes in dilution fluids. (B) Transmission electron microscope i ages for
morphological evaluations of exosomes. (C) Size distri utions of nanovesicles, evaluated with dynamic light scattering.
Data are expressed as the mean ± standard deviation; (D) Flow cytometry results show the abundances of control exosomes
(grey) and fluorescent nano-probes (blue). SCy MiExo: SCy 7.5-labeled milk exosomes; BDP-MiExo: BDP-FL-labeled milk
exosomes.
3.2. Characterization of Fluorescent Cancer Cell Line-Derived Exosomes
Similar to milk exosomes, U87 and B16F10 exosome solutions exhibited a strong
green color after labeling with SCy 7.5. Flow cytometry measurements in the size range
of exosomes showed fluorescence signal emissions in 99.94% of events with SCy-labeled
U87 exosomes (SCy-U87Exo) and 99.67% of events with SCy-labeled B16 exosomes (SCy-
B16Exo, Figure 2C). In unlabeled exosomes derived from U87 cells (U87Exo) and B16F10
cells (B16Exo), 3.03% and 4.95% of events, respectively, exhibited fluorescent signals at
778 nm.
Physicochemical characterizations of control and labeled exosomes showed that la-
beling had minor effects on the morphological properties of these cancer cell line-derived
exosomes. TEM imaging and DLS confirmed that SCy-U87Exo samples preserved the
morphology and size of the non-labeled controls (Figure 2A); the hydrodynamic sizes
were 132.00 ± 10.00 nm for control U87Exo and 135.32 ± 11.17 nm for the SCy-U87Exo
(Figure 2B). Labeled U87Exo also exhibited a similar core size of 123.20 ± 7.00 nm after
NTA analysis. However, the number of nanoparticles measured with NTA was slightly
lower for SCy-U87Exo, after the chemical reaction (2.25 × 109 ± 2.05 × 108 particles/mL),
compared to control U87Exo (3.35 × 109 ± 1.42 × 108 particles/mL).
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Figure 2. Physicochemical characterization of control and fluorescence-labeled cancer cell line-derived exosomes. (A)
Transmission electron microscope images show the nanovesicle morphology. (B) Size distributions of exosomes produced
with dynamic light scattering. Data are expressed as the mean ± standard deviation. (C) Flow cytometry results show
abundances of control exosomes and the fluorescent nano-probes. SCy: sulfo-cyanine 7.5; U87Exo: exosomes derived from
U87 glioblastoma cells; B16Exo: exosomes derived from B16F10 mouse melanoma cells.
TEM analyses confirmed that SCy-B16Exo showed typical exosome morphology.
However, DLS showed a slight reduction in size distribution, compared to the controls
(141.77 ± 1.00 for SCy-B16Exo n vs. 177.00 ± 13.00 for control B16Exo; Figure 2B). Th
NTA analysis confirmed the size reduction of the nanovesicles (139.3 ± 10.2 nm) and
revealed a slightly higher number of particles i the suspension of fluorescent SCy-B16Exo
compared to unlabeled B16Exo (5.91 × 108 ± 4.82 × 107 particles/mL vs. 9.59 × 108 ± 1.40
× 108 particles/mL).
3.3. In Vitro Stability of Fluorescent Exosomes
The temporal stability of exosome labeling was confirmed in a longitudinal in vitro
study with high performance liquid chromatography (HPLC). Fluorescent chromatograms
of BDP-MiExo showed a single peak at 25.2 min (Figure 3), which corresponded to the
retention time of pure unlabeled milk exosomes. No peak was registered at 38.3 min, which
was the characteristic retention time for free BDP-FL.
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A small peak was detected at a retention time of 3.8 min after 72 h of incubation,
corresponding to events higher than exosomes, probably due to their aggregation at long
time points.
It was not possible to assess the stability of exosomes labeled with SCy 7.5 (at 778 nm)
due to the limitations of the HPLC equipment. The upper limit of the absorbance detector
was 600 nm.
3.4. In Vitro Study of SCy-MiExo
The ability of cells to internalize these natural nanovesicles was assessed with confocal
imaging. Hepatocytes were exposed to both high (5 µg/mL) and low (0.5 µg/mL) doses of
SCy-MiExo, and fluorescent signals were observed in the cytoplasm, even at short time
points (1 h). The exosomes were distributed throughout the cytoplasm, especially in the
perinuclear region (Figure 4A,B), and uptake was dose-dependent (Figure 4C). The time
to the peak signal depended on the dose of exosomes added; in the near infra-red (NIR)
channel, the brightest signals were observed after 24 h of incubation at the high dose, and
after 4 h for the low dose (Figure 4C). Values registered at the end point of the experiment
(24 h) were statistically different if both dose. Moreov r, exosome uptake register d at
24 h in case of 5 µg/ml is highly significant compare to the other time points for the same
concentration (Figure 4D).
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3.5. In Vivo and Ex Vivo Studies with SCy-MiExo
In vivo whole-body optical imaging showed that SCy-MiExo was mainly taken up
in liver tissues (Figure 5A). The signal intensity in this organ increased over time, with
maximum values at 24 h (Figure 5B). The biodistribution examined ex vivo, in the organs
excised at 24 h, confirmed these results. Among all the organs studied, exosome uptake
was highest in the liver (Table 1). We also detected fluorescent signals in the spleen and
kidneys, but no significant uptake was detected in the other harvested organs (Figure 5C).
In contrast, in vivo imaging of the free dye showed a homogenous distribution
throughout the entire body, and drastic reduction in the fluorescent intensity was observed
after 4 h (Figure 5A). All of the excised organs evaluated ex vivo after 24 h post-injection
showed the free fluorescent signal (Table 1). The biodistribution profile of free SCy 7.5 was
absolutely different from that of SCy-MiExo (Figure 5C).
A histological study of the liver tissue (Figure 5D) showed high uptake and a homoge-
neous distribution of SCy-MiExo. Hematoxylin and eosin stained liver samples showed no
significant alterations in liver tissue structure. We only detected some minor alterations re-
lated to the exposure to nanometric ‘foreign bodies’, such as large accumulations of Kupffer
cells [23] or some vacuolization in hepatocytes, compared to the normal compartmentation
of glycogen inside these hepatic cells (Figure 5E).
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Table 1. Ex vivo average radiant efficiencies (p/s/cm2/sr)/(µW/cm2) of sulfo-cyanine 7.5-labeled
milk exosomes (SCy-MiExo) and free SCy 7.5 measured in organs excised at 24 h post-injection. Data
are expressed as the mean ± standard deviation.
Organ SCy-MiExo: Ex Vivo AverageRadiant Efficiency
Free SCy 7.5: Ex Vivo Average
Radiant Efficiency
Liver 3.36 × 108 ± 5.84 × 106 9.66 × 108 ± 2.20 × 107
Kidneys 1.12 × 108 ± 4.72 × 106 9.47 × 108 ± 7.72 × 107
Small intestine - 8.62 × 108 ± 3.50 × 108
Skin - 7.56 × 108 ± 3.53 × 108
Lungs - 5.35 × 108 ± 3.69 × 108
Intestines - 4.87 × 108 ± 2.03 × 108
Heart - 4.45 × 108 ± 1.13 × 107
Spleen 9.94 × 107 ± 4.63 × 106 3.48 × 108 ± 2.55 × 107
Brain - 3.29 × 108 ± 1.05 × 107
4. Discussion
Traditionally, the methodology employed in fluorescent exosome labeling for histolog-
ical and cellular assessments has relied on the passive integration of lipophilic dyes into the
exosome membrane [17,24]. However, passive integration implies a weak bond between
the exosome structure and the dye, which could lead to the detachment and release of the
fluorophore; the free fluorophore can produce false positives or increase the background
signal [17]. To resolve these limitations, the present study described a straightforward
methodology that ensured strong dye attachment to the exosome by creating covalent
bonds between the ester groups of commercial fluorophores and the amine groups present
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in nanovesicles. This chemical methodology relied on the disposition of free amine groups
from transmembrane proteins in the exosome membrane, and it was previously exploited
in other protocols for exosome surface engineering with bio-orthogonal functional groups
and radioisotopes [25,26]. To our knowledge, this study was the first to optimize this
approach for labeling exosomes and to facilitate optical characterizations.
To demonstrate the versatility of our approach, we tested two widely different com-
mercial fluorophores with different hydrophobicities, wavelengths, and chemical structures:
BDP-FL and SCy 7.5. Moreover, we tested the approach in different types of exosomes,
derived from goat milk and U87 and B16F10 cancer cells. The BDP-FL fluorophore (503
nm excitation) is typically used in preclinical studies of tissues and cells [27,28]. The
SCy 7.5 fluorophore (778 nm excitation) is an ideal tool for in vivo applications; it can be
detected in the NIR range, which provides relatively deep penetration and avoids the
inconvenience of autofluorescence [29]. Moreover, SCy 7.5 is highly soluble in aqueous
media, which provides an advantage over the more commonly used NHS ester dyes. For
example, Cyanine 7 requires organic solvents for the labeling reaction, which might be
toxic or otherwise harm these natural nanovesicles.
Exosomes isolated from goat milk were successfully labeled with both fluorophores.
Visually, the intense colors emitted by the purified samples clearly showed that the dyes
were incorporated into the exosome structures. Incorporation of the dye was confirmed
and quantified with flow cytometry, which showed that 99% of the exosome population
was labeled. Although it is well known that these natural nanoparticles are sensitive to
alterations in media conditions, our physicochemical characterization of labeled exosomes
showed that the morphological structure of these nanoparticles was not significantly
altered. We only observed a slight increase in the hydrodynamic size of fluorescently
labeled exosomes compared to controls. This change in size was most likely due to the
presence of the fluorophore on the exosome surface. Nevertheless, TEM analyses confirmed
that the vesicles were round, with an intact lipid bilayer membrane. The slight reduction
in the number of nanovesicles measured with NTA after the labeling reaction could be
attributed to some sample loss during the purification step.
We also tested our procedure with two different cancer cell line-derived exosomes
(U87 and B16F10). We employed SCy 7.5 for further in vivo experiments due to its conve-
nient physicochemical properties (high solubility and appropriate emission wavelength).
Moreover, BDP-Fl fluorophore requires organic media such as dimethyl sulfoxide (DMSO),
which could compromise the integrity of the cancer cell line-derived exosomes, less robust
than milk exosomes in degrading conditions [12,30].
Similar to the milk exosomes, both glioblastoma (SCy-U87Exo) and melanoma (SCy-
B16Exo) cell-derived exosomes showed an intense green color after dye binding. Moreover,
both samples were efficiently labeled, based on flow cytometry measurements. Similar to
the fluorescent milk exosomes, the physicochemical characterization of SCy-U87 exosomes
showed that both size and morphology were preserved after the labeling reaction. The
slight reduction in the number of nanovesicles detected with NTA could also be explained
by a small loss of nanovesicles during the purification step. In contrast, although SCy-
B16Exo samples showed preserved morphological characteristics, the hydrodynamic size of
these fluorescent exosomes was unexpectedly smaller than the size of unlabeled nanovesi-
cles, unlike our findings with the milk and U87 exosomes. Previous studies showed that
some exosomes tended to remain in an aggregated state after they are dispersed and stored
in a saline solution, due to their surface composition [31]. NTA and DLS analyses could
not distinguish between one big particle and two small, aggregated nanovesicles. Thus, ex-
osome surface labeling with fluorophores could reduce their tendency to aggregate, which
might lead to higher particle counts and more accurate size distribution measurements.
Large extracellular vesicles, which typically present electron-dense appearance and
irregular shape in TEM images [32] were not located in any of the samples analyzed,
supporting the exosome nature of the isolated nanovesicles from both milk and cancer cell
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lines. In addition, DLS and NTA registered homogeneous populations of nanovesicles in
the size range of exosomes (30–150 nm) [33].
One of the key points in the development of our chemical approach was the strong
attachment of the dye to the nanoparticle, which prevented detachment and release of
the free fluorophore. The high stability of labeled exosomes over time was demonstrated
with an in vitro longitudinal HPLC study. The absence of a secondary peak at 38.3 min,
associated with the free fluorophore, confirmed the absence of free BDP-FL in the sample
at all time points, even after 3 days. This finding highlighted the strength of the covalent
link established between the fluorophore and the vesicle structure. A small peak at 3.8 min
was only detected after long incubation times (72 h). That peak suggested that the milk
nanovesicles were beginning to aggregate because our size exclusion columns allowed the
larger molecules and nanoparticles to pass through first, and the smaller particles passed
through later.
For in vitro and in vivo assessments of these novel optical nanoprobes, we decided
to employ the SCy-MiExo vesicles because the milk exosomes showed promise as a
DDS [11,34]. We performed in vitro evaluations of SCy-MiExo internalization into pri-
mary hepatocytes with confocal imaging. The reason for choosing this cell line was that it is
well-known that the liver accumulates nanoparticles of 100–200 nm. We merged the green
fluorescent images from the cells with the NIR images of the exosomes and we observed
fluorescent exosome uptake even at short time points (30 min), which suggested rapid
incorporation, as reported in previous studies of exosomes in tumors and inflammatory
cells [35,36]. At all the studied time points, cytoplasmic accumulation was detected in
the perinuclear area, similar to findings previously reported for synthetic liposomes of
similar size [37]. This result indicated that these nanoparticles showed promise for use
as drug delivery platforms. The cellular uptake time curve showed maximal uptake at
different time points depending on the exosome dose. These time and dose effects were
previously described for milk exosomes incubated with cancer cells [11]. In our case, a low
dose (0.5 µg/mL) of SCy-MiExo showed the highest signal at 4 h, then it declined after
24 h. This pattern might reflect the fact that the total amount of exosomes was incorporated
inside the hepatocytes after 4 h, then the exosomes were digested by the cells, which led to
a decline in the fluorescent signal intensity at the latest time point (24 h). This behavior was
previously observed with other cell-derived exosomes, which pointed to the possibility
that nanovesicles were degraded after being engulfed by macrophages [35]. The high dose
(5 µg/mL) of SCy-MiExo was clearly taken up at initial points (1 and 4 h), but the brightest
signal intensity was recorded at 24 h. This result could be due to the high availability of
exosomes; thus, after 4 h, exosomes remained available in the cell culture for internalization
by hepatocytes at later time points.
The in vivo behavior of fluorescent SCy-MiExo was evaluated with optical imaging.
The SCy dye was selected because it showed high hydrophilicity and high intensity emis-
sion in the NIR range, which is far from the autofluorescence range of natural biomolecules,
such as hemoglobin [38]. We performed longitudinal in vivo imaging of the fluorescent
nanovesicles in healthy mice to evaluate their biodistribution over time. Liver accumu-
lation was observed at 1 h post-injection, which confirmed that these nanovesicles were
cleared rapidly, primarily through hepatobiliary metabolism. This in vivo biodistribution
and mainly hepatobiliary metabolism was consistent with the pharmacokinetic profile
observed in previous studies for small nanoparticles of similar size and shape, like synthetic
liposomes or metallic nanoparticles [39]. As a control, we evaluated the in vivo biodis-
tribution of the free dye. We observed high uptake of free SCy in the lungs, and a rapid
decline in the fluorescent signal; this decline was linked to rapid renal excretion, evidenced
by the high accumulation of free dye in the kidneys at 24 h post-injection. This behavior
was typical of free fluorophores [40] and other small molecules [41]. This clear difference
in the biodistribution profiles of free SCy 7.5 and fluorescent exosomes indicated that the
nanovesicle labeling was robust and stable. A previous study from our group showed that
the administration route affected the biodistribution of goat milk exosomes [42]. In that
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study, nuclear imaging showed the same in vivo biodistribution profile as that obtained
in the present study with fluorescent SCy-MiExo, which implied that our approach did
not modify the pharmacokinetic properties of the exosomes. Finally, our ex vivo imaging
study of the organs confirmed that exosomes mainly accumulated in the liver, spleen,
and kidneys, consistent with findings from previous studies that employed exogenous
exosomes [17].
In conclusion, we developed a technique for readily determining the natural biodistri-
bution of fluorescently labeled vesicles over time, without requiring the sacrifice of animals.
We showed that milk exosomes were mainly taken up and retained in the liver and spleen,
due to the phagocytic activity of Kupffer macrophages in these organs [43]. On the other
hand, our histological evaluation confirmed that SCy-MiExo accumulation did not cause
tissue damage or alterations in liver tissue structure. These observations opened up a
novel avenue of approach for deep research on the potential role of milk exosomes in
liver-targeting therapies.
This study presented a straightforward methodology for the covalent labeling of exo-
somes with commercial fluorophores. The reproducibility and robustness of the technique
were assessed with two different dyes and several types of exosomes (derived from milk
and two types of cancer cells). In all cases, we demonstrated the success of this chemical
approach and the preservation of the physicochemical properties of the nanovesicles.
The applicability of this approach was validated with different optical imaging tech-
niques. On the cellular scale, we demonstrated with confocal imaging that covalently
labeled exosomes were internalized in hepatocytes. The results confirmed that labeled
exosomes rapidly accumulated around the nucleus in a dose-dependent manner. Fluo-
rescent exosomes were also successfully visualized in vivo, where they showed behavior
similar to that observed for other synthetic nanoparticles, such as liposomes. These results
suggested that our approach could be used for non-invasive in vivo applications, and
that fluorescently labeled natural nanovesicles could serve as a substitute for synthetic
nanoparticles in therapeutic applications.
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